Ofina

Quick links to important sections

Ofina

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ofina

Property Description
Active ingredient Ofloxacin
Form Tablet (Oral), Solution (Ophthalmic, Otic)
Pharmacological class Fluoroquinolone Antibiotic
General purpose Clearing bacterial infections
Origin Synthetic

What is Ofina and What is its Active Ingredient?

Ofina is a pharmaceutical preparation classified as a prescription-only antibiotic whose core active ingredient is Ofloxacin. This compound is a synthetic chemical entity, belonging to the fluoroquinolone class of antimicrobial drugs. Ofloxacin is chemically defined as a racemate, containing both mirror-image forms of the compound. While often available as a single entity product, some formulations, such as the variant designated Ofina OZ, incorporate a secondary active compound, Ornidazole, which is used for its utility in managing mixed bacterial and protozoan infections.

Classification: Why is Ofina a Fluoroquinolone Antibiotic?

The established classification of Ofina as a fluoroquinolone antibiotic indicates its broad-spectrum antimicrobial capability against a wide array of bacteria. This distinction implies that the drug's fundamental function is a bactericidal effect, meaning it actively destroys bacterial cells rather than merely inhibiting their reproduction. Quinolone agents work by inhibiting essential bacterial DNA synthesis processes. The synthetic compound is manufactured in several key dosage forms, including the common oral tablet for systemic absorption and specialized preparations like Ophthalmic Solution and Otic Solution for targeted topical administration to localized infection sites.

What is the General Therapeutic Purpose of Ofina?

The general therapeutic purpose of Ofina is to manage or clear bacterial infections within the body by leveraging its ability to interfere with bacterial DNA management. This targeted action allows the synthetic fluoroquinolone to rapidly reduce the overall burden of pathogenic bacteria, which is the necessary foundation for resolving various types of infection. For instance, the oral tablet is typically used when systemic intervention against widespread pathogens is required, while the Otic Solution is used for localized ear infections.

Regulatory References

  1. NIH/NLM's mechanism of action of fluoroquinolones
  2. MedlinePlus on Quinolone Mechanism

What side effects are possible with Ofina?

Ofina (finasteride) is generally well-tolerated, but like all medications, it can cause side effects. Most side effects are mild and may lessen with continued use or resolve completely upon stopping the medication.

Sexual Side Effects

The most commonly reported side effects are sexual in nature and may include decreased libido (sex drive), erectile dysfunction, and ejaculation disorders (such as decreased volume of semen). Though uncommon, some men have reported these sexual side effects persisting even after discontinuing the treatment.


Other Potential Side Effects

Other less common side effects have been reported, including:

  • Breast changes: Tenderness, pain, or enlargement (gynecomastia).
  • Psychiatric: Low mood, depression, or, less frequently, suicidal thoughts.
  • Hypersensitivity reactions: Skin rash, itching, hives, or swelling of the lips, face, tongue, or throat.
  • Testicular pain.

If you experience any psychiatric symptoms, particularly depression or suicidal thoughts, or notice any breast lumps, pain, or nipple discharge, stop taking Ofina immediately and seek medical advice. These breast changes may be signs of a serious condition, such as male breast cancer.


Safety and Contraindications

  • Women and children should not use this medicine. Ofina is for use in men only.
  • Pregnant women or women who may become pregnant should not handle crushed or broken tablets, as the active ingredient can be absorbed through the skin and may cause birth defects in a male fetus. Whole, film-coated tablets can be handled safely.
  • Ofina can affect the results of the Prostate Specific Antigen (PSA) test, a screening tool for prostate cancer. You must inform your doctor that you are taking this medication before having a PSA test. While Ofina is not approved to prevent prostate cancer, the use of similar drugs has been associated with an increased risk of high-grade prostate cancer. Discuss your full medical history with your healthcare provider.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for an overdose of Ofina (Ofloxacin) describes specific clinical manifestations and mandates immediate emergency action due to the risk of severe systemic outcomes.

Documented Manifestations and Serious Risks

Overdose presentations primarily involve Central Nervous System (CNS) effects, which include confusion, drowsiness, dizziness, and slurred speech. Other documented signs include nausea, hot and cold flushes, and numbness and swelling of the face. Due to the nature of the fluoroquinolone class, regulatory documents highlight the potential for severe outcomes, specifically convulsions/seizures and serious QTc prolongation, which may lead to life-threatening cardiac dysrhythmias and requires continuous ECG monitoring.


Emergency Actions and Management

Regulatory labeling mandates that users seek emergency medical attention immediately and contact a Poison Control Center. This immediate action is necessary to manage acute toxicity. The official management procedures center on symptomatic and supportive treatment. No specific antidote is documented for Ofloxacin overdose. Procedural steps may include gastric lavage for recent ingestion. Regulatory guidelines further note that patients with severe renal impairment require special consideration and monitoring of serum concentrations due to reduced drug clearance.

Therapeutic Uses of Ofina

What Ofina Treats: Main Uses and Benefits

Ofina (Ofloxacin) is applied across domains where additional symptomatic support is needed in conditions presenting with systemic or localized discomfort. Its use is relevant in contexts involving heightened systemic burden, which may assist with easing the symptom burden. The medication is relevant for managing conditions that cause pronounced discomfort, including infections of the genitourinary system (e.g., cystitis, prostatitis, PID), the lower respiratory tract (e.g., pneumonia, bacterial bronchitis), and topical infections of the ear and eye.


Symptom Relief and Therapeutic Contexts

The medication may be part of symptomatic management in conditions where symptoms that interfere with daily functioning are present, such as cystitis, prostatitis, and pelvic inflammatory disease (PID). In systemic infection contexts, it is relevant for managing symptom clusters that may become intense, particularly those associated with a productive cough or systemic fever. When used in its specialized solution forms for localized conditions like otitis externa and conjunctivitis, it is applicable in conditions marked by periods of increased local irritation, and contributes to improved comfort. This symptomatic approach supports the patient during difficult episodes by easing distress.

“Used in areas where short-term symptom management is appropriate, Ofloxacin assists with maintaining functional stability during phases when symptoms become more noticeable.”


Quick Fact: Symptomatic Support
Ofina is commonly used across conditions presenting with acute episodes, assisting with easing the symptoms related to physical discomfort and systemic imbalance associated with urinary and respiratory system involvement.

Regulatory References

  1. NIH StatPearls Ofloxacin Indications Summary

Eligibility and Restrictions for Use

Official Population Eligibility Rules for Ofina

Ofina (Ofloxacin), a fluoroquinolone antibiotic, has strict population eligibility rules defined in regulatory labeling, primarily concerning age, physiological status, and pre-existing medical history.

Eligibility Classification Population Group Status in Regulatory Documents
Absolute Contraindication Hypersensitivity to Ofloxacin or any quinolone Must not use
Absolute Contraindication History of tendon disorders related to fluoroquinolones Must not use
Absolute Contraindication Children and growing adolescents (systemic use) Must not use (typically under 18 years)
Absolute Contraindication Pregnant or Breastfeeding women Must not use
Restricted Use/Caution Impaired Renal Function Requires dosage adjustment
Restricted Use/Caution History of Epilepsy or Seizure Disorders Use with caution
Restricted Use/Caution Patients with Myasthenia Gravis Avoid use (risk of exacerbation)

Systemic use is generally approved for adults who do not possess any contraindications. However, use in patients with impaired renal function is restricted and requires a dosage modification because the drug is primarily eliminated by the kidneys. Additionally, caution is specifically advised in older adults due to their increased susceptibility to reduced kidney function and a heightened risk of tendon problems. The use of the systemic form is contraindicated in women who are pregnant or breastfeeding, as well as in all growing children and adolescents.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures Ofloxacin's interaction profile around four primary types: pharmacokinetic effects on absorption and elimination, additive pharmacodynamic risks, metabolic interference, and required administration separation.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Agents (Examples) Official Regulatory Finding
Reduced Absorption Antacids (Aluminum/Magnesium), Sucralfate, Iron/Zinc preparations These agents form chelates with Ofloxacin, substantially reducing its systemic exposure.
Reduced Clearance Probenecid May interfere with renal tubular secretion, reducing Ofloxacin elimination and increasing plasma levels.
Additive CNS Risk Theophylline, NSAIDs (Fenbufen) Co-administration is formally noted to risk lowering the cerebral seizure threshold.
Additive Cardiac Risk QTc-prolonging drugs (e.g., Antiarrhythmics, Macrolides) Increases the documented risk of QT interval prolongation.

Timing and Population Restrictions

Agents that reduce absorption, such as metal-containing antacids and supplements, must be administered at least two hours before or two hours after Ofloxacin to prevent reduced exposure. Co-administration with Vitamin K antagonists (e.g., Warfarin) requires close monitoring of coagulation tests due to a reported increase in coagulation parameters. Furthermore, official labeling notes that impaired renal function and elderly patient status reduce Ofloxacin clearance, which may affect interaction severity.

Mechanism of Action

Disrupting Microbial Genetic Integrity

The primary action of Ofloxacin is to interfere with the fundamental processes that maintain the microbial genome. It achieves this by acting as a specific inhibitor of two essential bacterial enzymes, DNA Gyrase (Topoisomerase II) and Topoisomerase IV, which are required for DNA replication, transcription, and repair. This specific interaction stabilizes a toxic drug-enzyme-DNA complex, leading to an accumulation of irreversible double-strand DNA breaks that trigger bacterial cell death.


Complementary DNA Damage by Free Radicals

In the combination product, the co-active ingredient Ornidazole employs a distinct, complementary mechanism, primarily targeting anaerobic microbes and protozoa. Ornidazole is metabolically reduced inside these cells, generating highly reactive free radicals that are chemically unstable. These radicals inflict direct chemical damage by fragmenting the microbial DNA structure. This dual-mechanism approach provides a broader bactericidal spectrum by targeting different cellular vulnerabilities across a wider range of pathogens.


️ Mechanistic Limitations and Target Evasion

The function of this mechanism is constrained by the microbe's ability to evade the drug. Resistance often occurs when the microbial target enzymes, such as DNA Gyrase, undergo mutations which prevent Ofloxacin from binding, or when the bacterium increases the activity of efflux pumps that actively expel the drug. These evasion tactics reduce the intracellular concentration below the threshold required to induce lethal DNA breaks.

Dosage and Administration Information

How to Use Ofina

Ofina (Ofloxacin) is administered via specific, labeled routes defined by its dosage form, and its use is strictly guided by official regulatory dosing schedules. The medication is used either orally for systemic treatment or through topical solutions for localized infections of the ear (otic) or eye (ophthalmic). Both the Otic and Ophthalmic solutions are officially designated as not for injection.


Official Administration and Dosing

Administration Rule Detail
Standard Oral Dose Range 200 mg to 400 mg per dose; maximum daily dose is 800 mg.
Frequency Typically twice daily (q12hr), though doses up to 400 mg may be taken once daily.
Food Timing The oral tablet can be taken with or without food.
Co-Administration Constraint Oral administration must be separated by two hours from any preparations containing metal ions (e.g., antacids, sucralfate, iron) to prevent absorption reduction.

Population-Specific and Course Duration

Treatment duration varies significantly by infection, ranging from courses as short as 3 days up to 6 weeks for conditions such as prostatitis. The maximum overall duration should not typically exceed two months. For individuals with renal impairment (CrCl le 50 mL/min), a dose reduction or extended dosing interval is required. Similarly, the dose is officially recommended not to exceed 400 mg daily in patients with hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ofina (Ofloxacin)


Evidence for Systemic Use in Urinary Tract and Prostate Infections

The research base for Ofloxacin tablets largely consists of Randomized Controlled Trials (RCTs) and systematic reviews that have explored Ofloxacin in the context of both uncomplicated and complicated urinary tract infections (UTI) and chronic bacterial prostatitis. These studies were used in research examining how symptoms change over time and focused on populations with both simple and complicated UTIs, including some specialized studies in cohorts with chronic conditions.

Researchers primarily monitored two key outcomes: the microbiological clearance rate (whether the infectious bacteria were eliminated) and the clinical resolution of outcomes related to physical discomfort. Findings describe patterns observed in the studies where measurements of pathogen eradication were documented over the short treatment period. Comparative research against other antibiotic agents provided context related to short-term symptom patterns examined in the studies.


Evidence for Localized Use in Ear and Eye Infections (Topical Solutions)

The topical forms of Ofloxacin, used for local infections of the ear and eye, were evaluated through different sets of clinical trials, including multicenter studies. Research examined outcomes linked to inflammatory or irritative states. For otitis externa (ear canal infection), studies monitored the clinical cure rate, which focused on the resolution of local symptoms such as ear discharge. For bacterial conjunctivitis (eye infection), research explored clinical improvement and the observed clearance of bacteria from the eye surface.

Studies report how symptoms evolved in the observed populations, documenting measurements of clinical outcomes in both adult and pediatric cohorts over the typical short treatment course.


Long-Term Research and Durability of Outcomes

Most clinical trials for antibiotics are designed to measure short-term clinical response and microbiological success immediately after the treatment is completed. Follow-up durations were limited in many Ofloxacin studies, generally focusing on a test-of-cure visit within days or a few weeks post-therapy. This means that the long-term effects are not fully established.

There is limited information for long-term outcomes, particularly regarding the durability of microbiological clearance and the overall impact on the frequency of recurrence in conditions characterized by cycles of stability and flare-ups.


What Is Still Uncertain About Ofloxacin's Research Profile

A major area of uncertainty is the ongoing impact of antimicrobial resistance among bacteria, which may affect the generalizability of older clinical trial results. Furthermore, data for certain highly complex patient groups remain insufficient, meaning evidence quality varies across studies for these cohorts. While some older comparative trials exist, current comparative evidence against the very newest therapeutic options may be lacking.

Key Studies & References

  1. Ofloxacin: Pharmacology, Adverse Effects, Contraindications and Dosage (General Clinical Overview)

Frequently Asked Questions (FAQ)

Common questions about Ofina (FAQ)


Q: How quickly does Ofina usually start working?

A: Clinical studies often report a reduction in symptoms or bacteriologic cure within the typical short-term treatment course, which can range from a few days up to about 10 days, depending on the type of infection being managed. A noticeable effect may begin within the first few days of starting the medicine.


Q: What happens if I stop taking Ofina suddenly?

A: Regulatory warnings state that if treatment is stopped prematurely or doses are missed, there is a risk the infection may not be fully eliminated. Furthermore, stopping early may contribute to the bacteria becoming resistant to the medicine.


Q: Is there a risk of dependency with Ofina?

A: Ofina (Ofloxacin) is classified as a fluoroquinolone antibiotic and is not listed as a controlled substance under official regulatory schedules. Because it is not classified as a controlled substance, it is not associated with the typical risks of dependency that apply to scheduled medications.


Q: Is Ofina the same as [Name of similar drug]?

A: Ofina contains the active ingredient Ofloxacin, which belongs to the fluoroquinolone antibiotic class. While other medicines may be used for similar purposes or be chemically related, they are considered distinct medications, each with its own official use and safety information.


Q: How long can a person safely take Ofina?

A: The duration of use is specific to the infection being treated, with official courses generally ranging from a few days up to six weeks for certain chronic conditions. In most cases, the overall duration should not typically exceed two months.


Q: Does Ofina affect sleep?

A: According to the official product information, trouble sleeping, also known as insomnia, is a reported side effect associated with the use of this medicine. Any changes in sleep patterns are typically matters to be addressed in a healthcare consultation.


Q: Are there different strengths of Ofina available?

A: The oral tablet form of the medicine is officially available in different strengths. These often include tablets of 200 mg, 300 mg, and 400 mg.


Q: Does Ofina interact with vitamins or supplements?

A: Regulatory labeling notes that preparations containing metal ions, such as Iron or Zinc supplements, must be separated from Ofloxacin dosing. These mineral-containing products can interfere with absorption if taken too close together.


Q: Why is Ofina sometimes prescribed instead of other options?

A: The medicine is officially approved for managing specific bacterial infections, including certain types of urinary tract and skin infections. It is selected when its broad-spectrum action or route of administration is considered applicable for the identified bacterial pathogen.


Q: Is Ofina safe to use before driving or operating machinery?

A: Official guidance warns that the medicine can cause effects such as dizziness, lightheadedness, or reduced alertness. Official warnings state that activities like driving or operating machinery should be avoided until an individual knows how the medicine affects their alertness.


Q: Is Ofina available as a generic medicine?

A: Yes, Ofloxacin, the active ingredient in Ofina, is officially available in lower-cost generic forms, which are recognized as medically equivalent to the brand-name product.


Q: What should I do if I miss a scheduled dose of Ofina?

A: Regulatory documents include generalized guidance for missed doses, typically advising on a specific time frame for taking the missed dose, or skipping it if the next dose is due soon. Doubling up on doses is generally advised against.


Q: How does the way Ofina works differ from similar drugs?

A: Ofina belongs to the fluoroquinolone class of antibiotics. Its mechanism is to interfere with essential bacterial enzymes called DNA Gyrase and Topoisomerase IV, which is a distinct way of clearing infection compared to other classes of antibiotics.


Q: Is it true that Ofina is only for short-term use?

A: Yes, official labeling confirms that the medicine is prescribed for courses that are defined by the type of infection and are typically short-term. The length of time an individual takes it is predetermined based on the clinical indication.


Q: Does taking Ofina impact fertility?

A: Official information regarding the impact of Ofloxacin on the ability to become pregnant is limited. While some data exist from small studies, the evidence is not sufficient to confirm a definitive risk or lack thereof.


Q: Are there any specific lifestyle changes recommended while on Ofina?

A: Official guidance often recommends limiting time in the sun, avoiding sunlamps and tanning beds due to increased skin sensitivity while using the medicine. Caution is also generally advised regarding alcohol consumption.


Q: Is Ofina used to treat stress or anxiety?

A: No, Ofina is an antibiotic indicated only for the treatment of specific bacterial infections. It is not approved or officially indicated to treat conditions related to stress, anxiety, or other mental health disorders.


Q: Is Ofina taken for a specific period, or indefinitely?

A: The medicine is taken for a specific, predetermined period based on the infection being treated. It is an antibiotic and is not intended for indefinite or long-term maintenance use.


Q: Does Ofina cause any changes to skin or hair?

A: Reported skin-related effects include rash, itching, hives, or swelling. Official information focuses primarily on these hypersensitivity reactions rather than general changes in skin quality or hair loss.


Q: What patient groups were included in the main research for Ofina?

A: The main research included adults with systemic infections like urinary tract infections (UTI) and chronic prostatitis. Separate clinical trials also examined both adult and pediatric cohorts for localized, topical eye and ear infections.


Q: Is Ofina a controlled substance?

A: No, Ofina (Ofloxacin) is a prescription-only medicine but is not officially classified or scheduled as a controlled substance by regulatory bodies.


Q: Does Ofina interact with herbal products like St. John's Wort?

A: St. John's Wort may increase sensitivity to the sun, which is also a reported risk associated with taking Ofina. Due to this potential overlapping effect, caution is generally advised with co-administration.


Q: Are there any official warnings about taking Ofina?

A: Official warnings include documented risks related to the tendons (tendinitis or rupture), effects on the nervous system (such as confusion or anxiety), and potential worsening of a muscle condition called myasthenia gravis.


Q: Is the research evidence for Ofina considered strong?

A: The foundational evidence for systemic uses includes studies classified as Randomized Controlled Trials (RCTs). These are generally considered a high standard of evidence for assessing clinical outcomes such as microbiological clearance and symptom resolution.


Q: Does Ofina affect birth control effectiveness?

A: Official information states that some antibiotics, including Ofloxacin, may reduce the effects of hormonal birth control, specifically those containing ethinyl estradiol. This raises the potential for reduced contraceptive effectiveness.


Q: What happens if Ofina is taken with certain antacids?

A: Taking Ofloxacin at the same time as antacids that contain metal ions like aluminum or magnesium will cause the medicine to be poorly absorbed into the body. This reduction in absorption can significantly decrease its effectiveness in treating the infection.


Q: Are there any specific lab tests needed while taking Ofina?

A: Patients taking blood thinners, such as warfarin, require close monitoring of coagulation tests. Official documents also note that the drug may cause false-positive results in urine tests for opiates.


Q: Why do some people need to avoid taking Ofina?

A: People must avoid the medicine if they have a known hypersensitivity or allergy to any quinolone drug, or a history of tendon problems related to fluoroquinolones. It is also officially contraindicated for pregnant or breastfeeding women.


Q: Is Ofina commonly prescribed for pain management?

A: No, Ofina is indicated for the management of specific bacterial infections, such as those of the urinary tract and prostate. It is not approved or officially indicated for the sole purpose of pain management.


Q: Can I take Ofina with over-the-counter pain relievers?

A: Official labeling notes specific interactions with anti-inflammatory drugs (NSAIDs) like Fenbufen, which can increase the risk of CNS effects. Official sources should be consulted regarding co-administration to ensure there are no specific warnings for co-administration of other common pain relievers.


Q: Is it common to feel tired when starting Ofina?

A: The official product information lists a range of common side effects, primarily sexual in nature, but does not explicitly categorize general tiredness or fatigue as a common side effect of the medicine.


Q: Does Ofina affect blood pressure?

A: Regulatory documents mention an additive risk of QT interval prolongation (a change in the heart's electrical activity) when taken with other QTc-prolonging drugs. The medicine's direct effect on routine blood pressure changes is not a primary focus of the official warnings.


Q: Is a headache a known side effect of Ofina?

A: While the official documentation notes several central nervous system (CNS) effects, including dizziness and lightheadedness, headache is not explicitly listed among the more frequently reported side effects.


Q: What does the official drug label say about how Ofina works?

A: The official label describes the medicine as an antibacterial agent that works by inhibiting the essential bacterial enzymes DNA Gyrase and Topoisomerase IV. This action is necessary for bacterial DNA replication, leading to bacterial cell death.


Q: What are the serious, but rare, side effects mentioned for Ofina?

A: Serious, but rare, side effects mentioned in official sources include tendon rupture, increased risk of seizures, and rare but severe psychiatric symptoms like suicidal thoughts. Breast changes may also signal a serious underlying condition.


Q: Does Ofina affect mood or behavior?

A: Yes, the official labeling includes mention of central nervous system (CNS) effects. These can include psychiatric symptoms such as low mood, depression, and less frequently, suicidal thoughts.

How should Ofina be stored and disposed of?

How to Store and Dispose of Ofina?

Storing and disposing of Ofina (Ofloxacin) must follow official regulatory guidelines to maintain product integrity and ensure public safety.

Storage Requirements

Condition Regulatory Rule
Temperature Store at room temperature, away from heat.
Protection Keep the medicine protected from light and moisture.
Container Must be kept in the original container with the cap tightly closed.
Prohibition Do not freeze the medicine (especially solutions).
Safety Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Ofina must not be discarded with household trash or emptied into drains. Regulatory documents instruct users to consult a pharmacist or healthcare professional for guidance on proper disposal. This ensures the product does not enter the environment and is processed via an approved waste disposal method.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ofina found in:

A-Z Index: